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Abstract 
This study aimed to explore the IC empowerment through Comprehensive Intellectual Capital 
Management (CICM). This study was conducted using interpretive accounting research (IAR) 
especially interpretive research (IR) in management accounting. The informants of this study 
were managers of pharmaceutical companies, ex-managers, observers of pharmacy industry, 
and researchers of Intellectual Capital (IC). Data analysis technique was performed by stages, 
i.e. data collection, data reduction, data display, and conclusion. The result of this study 
indicated that there were three stages in IC empowerment, i.e. knowledge management, 
innovation management, and intellectual property management. Pharmaceutical companies in 
Indonesia were averagely still in knowledge management and innovation management stages. 
Only some big pharmaceutical companies have aimed intellectual property management. 
Empowerment could be performed on all components of IC (human capital, structural capital, 
and relational capital) and on all levels of CICM (knowledge management, innovation 
management, dan intellectual property management). IC empowerment through CICM by 
interpretive accounting research proved that such non-financial IC research could explore 
hidden assets and explore non-financial activities that could be used to develop company 
strategies to reach company goals and improve business performance and competitive 
advantage. 
 
Keywords: Comprehensive Intellectual Capital Management, Management Accounting, 
Interpretive Accounting Research 
 
1. Introduction 
Intellectual capital (IC) according to Bontis et al (2000), IFAC (1998), Marr (2008) consists 
of Human Capital (HC), Structural Capital (SC), dan Relational Capital (RC). As stated by 
Hermawan (2013) that according to some study results, IC proves to influence business 
performance, improve company value, improve organization effectiveness, competitive 
advantage and also create welfare for companies. Some positive advantages seem not known 
by managers of pharmaceutical companies. According to a study by Hermawan et al (2012), the 
managers do not know and understand much about their IC components, do not know how to 
measure and manage, both IC individually and IC in integrated way. It is strengthened by a 
study by Sampoerno (2007) that IC management by pharmaceutical companies in Indonesia is 
still weak. Only 17% of pharmaceutical companies in Indonesia prove that they can compete in 
export market especially in Southeast Asia. 
Meanwhile, IC empowerment efforts must be continuously performed because a 
difference occurs between the obtained advantage and existing implementation reality. One of 
IC empowerment efforts can be performed by Comprehensive Intellectual Capital Management 
(CICM) (Al-Ali, 2003). CICM consists of three stages, i.e. knowledge management, innovation 
management, and intellectual property management. When observing each existing stage in 
CICM, this concept is perfect to implement because it is complete for each stage and for each 
IC component. Such IC empowerment effort will be appropriate if it uses non-financial IC study 
as an effort to explore hidden assets, explore non-financial activities, communicate value 
trigger, and recognize company characteristics in CICM stages. By considering the 
recommendation from Hermawan (2013) that non-financial IC study more uses qualitative 
research with interpretive as an approach. Therefore, this study aims to explore IC 
empowerment through CICM using interpretive accounting research. 
 
2. Literature Review 
The Resource Based Theory dan An Intellectual Capital View of the Firm 
Basic theory used in this study is the resource based theory and an intellectual capital 
view of the firm (ICV). The resource based theory (RBT) (Wernerfelt, 1984; Barney, 1991) was 
used in this study because according to this theory, company would obtain competitive 
excellence and superior performance if it could use company resource, both tangible resource 
and intangible resource. However, along with developing intangible resource in knowledge 
economy area, the role of intangible asset is getting big, including IC. Even Belkaoui (2003) 
states that IC qualification as strategic asset is located on potential relationship between IC and 
firm performance. It means that IC is strongly related to company performance, both financial 
and non-financial. Meanwhile, technically ICV states that IC is an important factor for company 
profit in long-term and company performance in knowledge-based economy (Hsu dan Fang, 
2009; dan Kong, 2010). IC also provides an important contribution for performance because its 
capability in using knowledge resources effectively. As a new theory or view, ICV is expected to 
provide a higher potential for empirical testing compared to RBV that represents certain 
narrower aspects connected to company competition excellence. In this way, ICV can be 
perceived as a complement to understand knowledge-based view broadly, as an effort to 
improve superior performance (De Castro et al. 2011). 
 
Comprehensive Intellectual Capital Manajemen (CICM) 
Meanwhile, some theories regarding IC empowerment and management have been 
stated by some experts, one of them is Comprehensive Intellectual Capital Manajemen (CICM) 
by Neirman Al-Ali in 2003. CICM model is a model designed to manage all forms of IC through 
three stages, i.e. knowledge management, innovation management, and intellectual property 
management. The thing differentiating this model with other IC management is in the keyword of 
“comprehensive”. It means that Al-Ali (2003) tries to provide a solution to manage IC starting 
from collecting and exploring knowledge resource, use it for innovation, and use it for company 
competitiveness and obtaining profit. 
The three stages or functions of CICM are the basic of business management that will 
always exist in each organization. The first stage related to resource providing for operational or 
production. The second is the continuation of the first stage because in this stage, the existing 
resources will be changed with various processes to produce valuable asset. In the third stage, 
the resource that has been valuable will be attempted to be elevated so as to optimize for the 
purpose of stakeholders. 
Based on the business management stage, CICM model tries to connect between 
business stages and function classification of IC. While the stages of IC management and 
development consist of: 
1. Knowledge resources,  
2. Innovation resources and processes, 
3. Intellectual property. 
In each stage, it is then processed by connecting each stage with IC components (HC, SC, and 
RC). The following are examples of connection between each stage of CICM with IC component 
presented in Table 1.  
Table 1. Types and Stages of CICM Model-Based IC 
IC Stage of 
Development 
Human Capital Customer Capital* Structural Capital 
Knowledge 
Management Stage 
Tacit knowledge, 
experience, 
brainpower, vision 
Experience, 
knowledge, 
relations, networks 
IT databases, 
knowledge base, best 
practices, culture 
Innovation Stage Ideas, product, 
concept, skills 
Ideas, product, 
concept, feedback, 
relationship 
Work systems, 
business processes 
Intellectual Property 
Management Stage 
Know-how, know 
why 
Brand identity, 
reputation, strategic 
alliances 
Patents, trademarks, 
copyrights, trade 
secrets 
* In this writing, Customer Capital is equalized with Relational Capital 
Source: Al-Ali (2003: 64) 
Based on Table 1, it can be seen that each stage of IC development is always connected 
to HC, RC, and SC. In each stage, maybe there are some same examples of resources, but 
different in context of resource providing and development. For example, experience in 
knowledge management state for HC and RC. Similarly in innovation management stage, there 
is ideas that also exists in HC and RC. 
If each stage in Table 1 is explained, CICM model will appear as Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. CICM Model (modified by the writer) 
(Source: Al-Ali, 2003: 66) 
 
Based on Figure 1, it can be seen that CICM model used to manage IC on each level in 
business and each stage will support the next stage. The first step, i.e. creating value by 
performing knowledge management on knowledge and brainpower. The first step will support 
the second stage, i.e. extracting value by performing innovation management on prototypes of 
new products or services. The last or third step is maximizing value on intellectual property 
management on competitive tools. Through the three stages, the distribution of each stage is 
clearly observable so that it is expected that overlapping of step will not occur in IC 
management. 
Based on Table 1 and Figure 1, the next steps can be arranged related to management 
objectives of the three stages of IC management. Table 2 describes that matter. 
 
Table 2. Management Objectives and Purposes for CICM 
CICM Stage IC Group Purpose Management Objectives 
Knowledge 
Management 
Raw 
knowledge 
resources 
Value Creation Recognize and leverage the 
knowledge resources required to 
sustain the organization’s processes 
Innovation 
Management 
Innovation 
processes and 
resources 
Value Extraction Unleash and Reconfigure innovation 
resources to create new ways of 
doing business and new products 
faster 
Intellectual 
Property 
Management 
Intellectual 
property 
Value 
Maximization 
Enable the use of intellectual 
property to enhance the 
organization’s competitive positioning 
and revenue generation 
Source: Al-Ali (2003: 66) 
 
Each stage will bring different management objective consequence. The objectives provide a 
guide for management to measure performance in each stage. The first objective is to manage 
good information flow and knowledge resource, i.e. to facilitate organizational learning and 
maintain all things related to organization (value creation). The main objective is to change a set 
of management objectives, i.e. in providing main knowledge resource for organization by 
connecting the objectives and facilitating knowledge distribution to encourage the existence of 
organization knowledge. Investment in this stage is not like in the other two stages because 
investment in this stage is a very long-term investment and unrelated to finance directly. 
Management innovation stage has main objective, i.e. extracting value from all existing 
knowledge resource for organization using innovation process. IC management challenge in this 
stage is how to manage innovation resource by strengthening the network inside and outside 
company so as to rearrange various things related innovation to gain trust from market. The last 
 Human Capital Structural Capital Relational Capital 
 
Competitive 
Tools 
 
Maximize Value: IP Management 
Prototypes of 
new product & 
services 
 
Extract Value: Innovation Management 
Knowledge & 
Brainpower 
 
Create Value: Knowledge Management 
stage, i.e. managing intellectual property is optimizing value on stakeholders using legal 
company property as competitiveness and marketing tools.  
 
3. Research Method 
This study explored IC empowerment through CICM using interpretive accounting 
research. The intended meaning is the meaning of what felt and experienced by key informants 
on CICM concept and competitive advantage. To understand the meaning, the researcher used 
qualitative interpretive research approach (Strauss and Corbin, 2003) and more specifically as 
interpretive accounting research (IAR) or interpretive research (IR) in management accounting 
(Lukkaa and Modell, 2010). Thus, analysis unit of this study was opinion or comment of key 
informant on CICM concept and competitive advantage. 
Data were collected in three methods, i.e. in-depth interview, focus group discussion 
(FGD), and documentation. In-depth interview was conducted with each informant. FGD was 
conducted by selecting some appropriate informants and documentation was conducted by 
archiving some secondary data, both existing in pharmaceutical companies and in other 
sources. With this method, complete data were obtained according to intended purpose of this 
study. 
Informants of this study were managers of pharmaceutical companies (KK, ER, DS, AP 
informants), supervisor (NA informant), ex-managers (YAS informants), IC researchers (ZF and 
WH informants), and pharmacy industry observers (UA and DH informants). Thus, in this study, 
there were ten key informants. Key informants from pharmacy manager element consisted of 
HRD manager, operational or production manager, and marketing manager. The use of key 
informants from manager element was absolutely implemented because it was related to three 
components of IC, i.e. human capital that was a representation of HRD, structural capital that 
was a representation of operational or production department, and RC as a representation of 
marketing department. It was in accordance with a study by Hermawan (2013) that the three 
managers had important roles in IC management in pharmaceutical companies. The 
determination of informants in this study was conducted by judgment and snowball (Marshall, 
1996). Judgment was conducted at the beginning before conducting field research, while 
snowball was conducted when field research was ongoing. 
Data validity test was conducted by credibility, transferability, dependability, and 
confirmability test (Senton, 2004). Credibility test was conducted by method triangulation, data 
source triangulation, theory triangulation, and triangulation among researchers (Hussein, 2009; 
Rahardjo, 2010). Transferability test was conducted by arranging qualitative report that was 
understandable, clear, complete, trustworthy, and parsimony because in qualitative research, 
the researcher could not guarantee the level of transfer of a study on other situations. 
Dependability or auditability test was conducted by implementing audit process on all research 
processes. In this study, dependability test was conducted by senior researchers, i.e. Prof TS, 
Prof SS, and Dr. BP. Confirmability test was conducted by asking for comments from other IC 
researchers, i.e. IU, IU, SLWI, MBW, and SH. 
Data analysis technique was implemented when the study was ongoing. It was in 
accordance with recommendation from Miles and Hubberman (1984) regarding data analysis 
technique for qualitative research. While the stages of data analysis were data collection, data 
reduction, data display, and conclusion. In data collection stage, the researcher collected all 
data obtained from in-depth interview, FGD, and documentation. After that, the researcher 
implemented data reduction by reducing some data that were not appropriate with the aim of 
this study. In this stage, the researcher used coding in data so that the data were divided into 
same themes according to the aim of this study. The next process was data display, i.e. the 
researcher presented the data that was reduced into same themes in form of narration so that 
the researcher could draw conclusion easily as the last stage in data analysis of qualitative 
research. 
 
4. Result and Discussion 
To obtain study result that was appropriate with the aim of this study, the researcher 
implemented some research stages. The first stage was combining all data obtained and 
conducting credibility test, i.e. method triangulation and data source triangulation, at once. In 
this stage, the researcher collected data and testing the data validity at once. For example, the 
result of interview with informant A was cross-checked with the opinion of informant B or the 
opinion of informant A was cross-checked with the result of documentation or the data of 
interview result and documentation were cross-checked with the data of FGD. It was quite 
possible because the qualitative researcher was the research instrument itself. In this stage, the 
researcher also conducted theory triangulation by comparing the result of this study and the 
theory used, for example, the knowledge-based theory (Sveiby, 2001), and the intellectual 
capital view of the firm (Brooking, 1996; Edvinsson and Malone, 1997). The second stage was 
implementing coding on the result of first stage process. Implementing coding facilitated the 
researcher to arrange same theme or concept as a result of this study. In coding process, some 
data were eliminated or unused because they were irrelevant with the aim of this study. While 
the result of this study form same data or concept from the result of data analysis are the 
following: 
 
Table 1. Same Concept or Theme 
Coding Same Concept or Theme 
A Position of Pharmaceutical companies in Indonesia in CICM Stages 
B IC Empowerment in CICM Concept 
 B1. IC Empowerment in Knowledge Management Stage 
 B2. IC Empowerment in Innovation Management Stage 
 B3. IC Empowerment in Intellectual Property Management Stage 
Date Source: Data Display of Coding and Data Reduction Result 
 
A. Position of Pharmaceutical companies in Indonesia in CICM Stages 
When conducting interview and discussion with the informants related to CICM stages, 
the researcher explained first regarding management objectives of each CICM stage. The 
objective of knowledge management stage was to recognize and use knowledge resources 
needed to maintain organization process. The objective of innovation management stage was to 
accelerate and configure innovation resources to create new methods and new products more 
rapidly. The objective of intellectual property management stage was to use intellectual property 
to improve organization competitive position and obtain profit. 
Based on description on objectives of CICM stages, the researcher asked the informants 
regarding which stage the average position of pharmaceutical companies in Indonesia was in. 
The informants responded that at that time, pharmaceutical companies in Indonesia were 
averagely in knowledge management and innovation management stage. Only some big 
pharmaceutical companies that had aimed for intellectual property management. Small and 
medium pharmaceutical companies were still in innovation management and knowledge 
management stage. It was because Indonesian pharmacy products were still me too products 
and maklon products. Regarding this matter was explained by informant ER as the following: 
 
“If it is observed from the model, in my opinion, averagely still in the second stage, 
innovation management, and the first stage, knowledge management. Those aiming for 
the third stage are still few, only some in Indonesia, maybe the big ones have thought 
about that. But the low and medium classes are still in level 1 or level 2. Because the 
characteristic of products of pharmaceutical companies in Indonesia is still me too and 
maklon or producing medicines in other’s factory.” (Excerpt of interview with informant 
ER) 
 
The statement from informant ER was the same as the opinion from informant KK, and clarified 
by informant AS, as the head of industry department of GP Pharmacy Indonesia, East Java. 
According to him, many pharmaceutical companies in East Java were still like Micro, Small, and 
Medium Enterprises. All activities were performed in one location, meaning that the facility for 
production, office, warehouse, and other was limited. 
 
“In East Java, there are many that are medium and low level. Even there are some that 
are similar to Small and Medium Enterprises. So, all becomes one. For cooking, living 
room, bedroom still become one, that’s the parable. But, PT “I” and PT “BF” are already 
good.” (Excerpt of interview with informant AS) 
 
Opinion similarity among informant ER, KK, and AS was as a part of data validity especially in 
credibility data of data source triangulation. 
Based on the opinions of the informants, it could be known that pharmaceutical 
companies in Indonesia were averagely in knowledge management and innovation 
management stage. In knowledge management was mostly performed by low-class or small 
pharmaceutical companies. It was because the objective of knowledge management stage was 
to recognize and use knowledge resources and intangible assets needed to maintain 
organization process. The existence of words “maintain organization process” was the reason 
why the informants perceived that in this stage, companies still implement internal repair so that 
the business process could keep going or the company could survive. 
The informants also perceived that pharmaceutical companies in innovation management 
were medium-level pharmaceutical companies. It was because the objective of innovation 
management stage was to accelerate and configure innovation resources to create new 
methods and new products more rapidly. The existence of words “innovation and new methods” 
was perceived by the informants that the companies started to find “exit” by new methods to 
develop products. Internal management was getting better so that the company effort to “exit” 
started to be implemented by innovation and new methods. 
The informants also perceived that pharmaceutical companies in intellectual property 
management stage were high-level pharmaceutical companies. It was because the objective of 
intellectual property management was to use intellectual property to improve organization 
competitive position and obtain profit. The existence of words “intellectual property” caused the 
informants perceiving that the companies had had leader products and good brand image for 
products and companies. Similarly with words “organization competitive” meaning that the 
company was ready to compete in national, Asian region, and international level. 
The informants’ perception could not be blamed, but it was not always right. It could not 
be blamed because based on text meaning of objectives of each CICM stage stated that. The 
opinion was not always right because based on in-depth interview with the informants, it 
obtained some examples that high-level pharmaceutical companies was also not good in 
managing HC. For example, pharmaceutical company BF that could be categorized as upper 
medium level company, but the HC management was not properly organized. Similarly, its 
organization culture (SC) still did not indicate a professional culture. Its RC also did not always 
use marketing-oriented strategies, but mostly used sales-oriented strategies. 
 
B. IC Empowerment Through Comprehensive Intellectual Capital Management (CICM) 
Model 
To come at a conclusion about the IC empowerment, the researchers conducted an 
analysis of data at the time of data collection, coding, data reduction, and data analysis along 
with the theory that supports the interpretation, i.e., the knowledge-based theory (Sveiby, 2001), 
and the intellectual capital view of the firm (Brooking, 1996; Edvinsson and Malone, 1997). It is 
also intended as an attempt to do a credibility test or the credibility of the data, especially on the 
triangulation theory. According to the knowledge-based theory, companies need to manage 
knowledge in the knowledge-based economic era as it is today. To do so, companies need 
knowledge transfer or knowledge conversion also. Alternatively, it can also performs knowledge 
management. Meanwhile, an intellectual capital view of the firm stated that IC is an important 
factor for long-term corporate profits and performance in the era of knowledge. Therefore, the IC 
must be empowered. In this study IC empowerment is conducted by CICM model (Al-Ali, 2003) 
Efforts to manage and empower the IC component can be through the CICM. CICM 
concept consists of three stages, namely knowledge management, innovation management, 
and intellectual property management. Each stage has a different purpose. Stages of 
knowledge management aims to create value (value creation), the stages of innovation 
management aims issued value (value extraction), and the stages of intellectual property 
management aims to maximize the value (value maximization). 
 
B.1. IC Empowerment in Knowledge Management stage  
The purpose of the knowledge management stage is to identify and exploit knowledge 
resources needed to sustain the process of organization or business processes as well. 
Keywords of this objective are to recognize, utilize, and maintain. This means, that at this stage 
the company is still in the stage of recognizing prior knowledge resource or intangible assets 
owned by companies then use it in order to survive in the business process. Thus, it can be said 
also that at this early stage the company is required to perform business processes properly in 
accordance with generally accepted procedures or companies that are in this stage it is still 
doing the internal management arrangements. 
At that time, FGD also discussed about the characteristics of the pharmaceutical 
companies that are at this stage of knowledge management. FGD implementation intention is to 
acquire and sharpen the data as well as to test the credibility particularly triangulation method, 
triangulation of source, and triangulation among researchers. Pharmaceutical companies will be 
easier to identify the empowerment that must be done in optimizing the IC by identifying the 
characteristics of companies that are in the stages of knowledge management. In the opinion of 
the FGD participants that pharmaceutical companies that get the knowledge management level 
is still limited of its resources whether its human resources, finance and capital. Consequently, 
the development of HC, is still limited to general theories applicable because it can not bring in 
outside consultants who can give planned and well business advises. That is, the 
pharmaceutical companies in this stage indeed does not require high competence or only have 
a standard competency, that is only to produce the drug alone. 
The characteristics of existing HC pharmaceutical company in CICM stages can also be 
mapped by its hierarchy. If it is still in the knowledge management stage called personnel, 
whereas if it in the management innovation stage is called human resource, and that in the 
intellectual capital stages is called human capital. Following is AP opinion:  
 
"If in terms of function, the tendency of the company is still at the knowledge 
management level of the HC is still functioning as personnel. Then when they climbed 
into innovation management stage then it will turn into a human resources function and 
eventually became human capital for intellectual property management "(AP’s Opinion on 
FGD) 
 
Characterize in the SC component is internal management which is still not well ordered. 
It means, at this stage, the company's management is still not able to perform a variety of 
innovations and creations because it is still confused with management of intern problems and 
also keep the company survive. Resource limitations, such as engines, space, and equipment 
led to the inability of the company to produce drugs that are detailed and need special handling, 
such as injection, infusion, and sterile medicines. When viewed from the product, certainly not 
the leader product because the company still seeing the development of the market, about what 
products are well sold in the market, after that they will be produce me too product. 
Characteristic associated with the RC owned by pharmaceutical company at this 
knowledge management stage is the pharmaceutical market share in the lower middle level. 
That is, naturally formed so. Relationships with doctor only appear in sub-urban doctors or 
lower-level health workers such as midwives. The use of advertising media as a promotional 
tool also has not been conducted. Similarly, the CSR activities, which are still limited even rarely 
conducted. 
Based on the opinions of the informants, it may be an attempt to empower HC, SC, and 
RC owned by pharmaceutical companies. Some of empowerment that can be done is by the 
improvement in the process of employee recruitment or recruitment system that must be done in 
the right way, the standard of training shall be provided to the employee. Other efforts can be 
done with the existing knowledge sharing within the company, the minimum equipment that 
must be met to the satisfaction of CPOB for drug production, an improvement over the 
company's organizational culture and also the relationship between doctors which should be 
improved. 
This is perceived by the informants about IC empowering knowledge management in 
stages. Empowerment which is still in its prior stages conducts internal reforming and also 
recognizes its knowledge resources. The beginning process which has to be empowered is 
revamping employee recruitment management system. The next process is to meet the 
standards that must be met by pharmaceutical companies related to the number of pharmacists. 
The standard to be met is a minimum of three pharmacists. 
The next is to optimize the empowerment training that followed by employees. Usually 
what happens is the pharmaceutical company sent one of his employees for training or 
seminars, that employee must share knowledge gained to other employees. This is called 
knowledge transfer. Knowledge sharing can also be done by dividing the experience possessed 
by senior employees to junior employees. Knowledge sharing and knowledge transfer can use 
the concept of SECI (Socialization, externalization, Combination, Internalization). It is important 
for the repairing and improvement of knowledge, skills, and attitude which is owned by the 
employees. Empowerment can also be done by giving satisfaction to strengthen the employee’s 
loyalty. 
Empowerment also shall be done on the SC component in knowledge management 
stages. Empowerment on a lean organizational structure should make pharmaceutical 
companies more efficient and effective in strategic decision making. Although the internal 
management is not well ordered, pharmaceutical companies must also be able to utilize a 
variety of intangible assets owned, although it is still very limited. Optimization of empowerment 
infrastructure, machinery, equipment, and information technology must be able to meet the 
requirements of CPOB. That is, all the resources and technology organizations should be 
empowered to meet the drug quality standards appropriate the CPOB requirements. 
Empowerment on RC components should also be made at this knowledge management 
stage. It is usually done is to convince the doctor that me too products proprietary have the 
same qualities as a leader product. Another empowerment is to optimize the cooperation that 
has been done with other health professionals, or also expand cooperation with new users 
according to the ability of the company. 
Based on the above results, the characteristics and the IC empowerment on the 
knowledge management stage are as follows: 
1. The company is still limited in funding and therefore contributes to the development of HC. 
That is, HC still struggling on its own merits so can not innovate because there is no input or 
advice of a consultant or has not been able to do a study out of the company. HC also still 
not be able to innovate because they dwell on the tasks management and company’s 
internal housekeeping. 
2. HC held still very standard or do not require high competence. At this stage the employee 
more positioned as personnel. 
3. The product produced was not a pharmaceutical product that is complicated because it takes 
machinery, equipment, and technology (SC) that meets certain specifications. Product (SC) 
generated still join the leader product. The company at this stage is still waiting for what 
product demanded by the market. Once the company knows it will be made a product that is 
me too product. 
4. The RC’s done already segmented into lower middle market share. Similarly, the doctors 
who become the working partners of pharmacy, will be segmented physician grade C or also 
suburban doctor, midwives, and health workers in the clinic-polyclinic. 
5. HC Empowerment can be improved in the process of employee recruitment or recruitment 
system should be done in the right way according to the standards of training that must be 
given to the employee. Empowerment HC can also be done with existing knowledge transfer 
within the company. Knowledge sharing between experienced employees with new 
employees, or between senior employees with junior employees. 
6. SC Empowerment is conducted in a lean organizational structure optimization in strategic 
decision making for more efficient and effective. Optimization of empowerment infrastructure, 
machinery, equipment, and information technology must be able to meet the requirements of 
CPOB. 
7. RC Empowerment can be done by always keeping the physician relationship which must be 
maintained to be improved and always trying to find the new users from the other health 
personnel.  
 
Based on these characteristics, the HC empowerment that can be done is the 
improvement in the process of employee recruitment or recruitment system that must be done in 
the right way according to the training standards that should be given to the employee. SC 
Empowerment can be done with minimal equipment procurement to be met to the satisfaction of 
CPOB for drug production, an improvement over the company's organizational culture, and 
maintain the quality of the product in accordance with CPOB. RC empowerment can be done by 
always keeping the physician relationship which must be improved.  
Based on the above description, and also based on the meaning of the text on the 
knowledge management stages purposes, is true that a pharmaceutical company in this stage 
still perform a management arrangement, still recognizes and tries to use its limited resources. 
Because of the limited resources both for HC, SC, and RC, pharmaceutical companies must be 
able to utilize it’s owned to be empowered on its role in supporting the company's operations 
and performance. The way to do is to knowledge management process. In the process of 
managing this knowledge, pharmaceutical companies must be able to recognize and utilize the 
explicit knowledge and tacit knowledge of the company and employees. Explicit knowledge 
related to visible-knowledge, such knowledge is written, archived and spread in a book or other 
printed form. Tacit knowledge associated with invisible knowledge, such knowledge in the form 
of know-how, experience, skills, understanding that employees. In this process of knowledge 
management, small-scale level pharmaceutical company or below can utilize the explicit 
knowledge for various purposes, e.g. for the development of employee skills, to improve 
processes and procedures, as well as materials do networking with other parties. 
Pharmaceutical companies can also take advantage of tacit knowledge of employees which 
have to be converted into explicit knowledge. The experience and skills of employees in the 
form of tacit knowledge can be transformed into explicit knowledge, such as various kinds of 
rules, operating system procedures, or modules also work to improve the performance of the 
employee and the company. 
Utilization of knowledge can also be done through the interaction of IC components. That 
is, knowledge transfer between the IC components can be associated with each other. 
Utilization of knowledge consists of six groups, namely knowledge transfer from HC to RC, 
knowledge transfer from RC to SC, knowledge transfer from SC to HC, knowledge transfer from 
the RC to the HC, knowledge transfer from SC to RC, and knowledge transfer from HC to SC. 
Table 2 describes the utilization of knowledge through the interaction of the IC component. 
 
Table 2. 
UTILIZATION OF KNOWLEDGE THROUGH  
THE INTERACTION OF IC COMPONENTS 
Knowledge transfers from 
HC to RC 
Knowledge transfers from RC 
to SC 
Knowledge transfers from SC 
to HC 
Employees who had just 
finished training or 
seminars giving advice on 
market orientation or 
changes in consumer 
behavior of pharmaceutical 
products 
The marketing sections, share 
experiences about what is 
perceived by the customer 
about the drug quality or both 
the packaging and solubility 
Operational or production 
sections provide information 
about the new rules and 
regulations that exist in CPOB 
so training is necessary for the 
production employees 
Knowledge transfers from 
RC to HC 
Knowledge transfers from SC 
to RC 
Knowledge transfers from HC 
to SC 
The marketing sections 
giving advice on med rep 
quality when doing 
presentations with the 
doctor, and also the quality 
of the sales team  
Operational sections provide 
training on new technologies 
that are used for drug 
database system and also 
companies customer  
Senior managers give an 
explanation of the 
organization's strategic 
objectives plan 
Source: Hermawan, 2012.  
 
B.2. IC Empowerment in the Innovation Management Stages  
The management purposes of the innovation management stage are to facilitate and re-
configure the resources of innovation to create new ways and new products more quickly. There 
are lots of keywords in the phrase, i.e. smooth, and re-configure, resource innovation, creating 
new ways, and new products. It means, the company has been able to identify knowledge 
resources, exploit, even started to accelerate and configure them into the resources of 
innovation. The company at this stage has begun established in matters of internal 
management that have started to "come out" to innovate and create new ways and new 
products. 
At the time of FGD also discussed about the characteristics of the pharmaceutical 
companies in the innovation management stages. By identifying these characteristics, it will 
facilitate the identification of empowerment that must be done in order to optimize the 
company's IC. Some opinions of the FGD participants is the product innovation can be done by 
reformulating or also by producing the new products. New products in the company concerned, 
but it already in the pharmaceutical industry. Some are of the opinion that innovation is not only 
creating new products in the company, but also to develop the business into a conglomerate 
business. 
Characteristic of innovation in this stage is the source of innovation by the company can 
be derived from the company's consultants or also from the marketing team. Innovation has 
also been carried out by a separate department, the department of research and development. 
Innovations are reformulated or also business development towards the healthcare business. 
Innovation can also be a new product in the company, but in the market has long existed. That 
is, a new pharmaceutical company to innovate on the drug after the drug is a very good market 
share. Innovation is not only related to new products are produced, but also about cost 
efficiency and effectiveness of work. 
Based on the opinions of the informants, it can be done an IC empowering in innovation 
management stages. HC Empowerment on innovation management stage is to provide training 
that really supports creativity and innovation. The result of knowledge, skills, and attitude of 
employees increased so as to empower all existing enterprise resources. At this stage, the 
employee is no longer functioning as personnel, but rather functions as human resources. The 
knowledge enhancement task can be done with short courses or even sending for special 
education in college. 
Knowledge sharing and knowledge transfer also occurs at this stage, but the existence of 
a management consulting owned by pharmaceutical company that make the transferred 
knowledge become more meaningful and useful again. Management consultants will provide 
advice on a variety of things that exist in pharmaceutical companies, mainly related to human 
resources management. Knowledge transfer can be done through in-house training and also 
regular meetings conducted by the Company. This empowerment is what should be used by 
pharmaceutical companies to improve the competence of its employees. 
Meanwhile, the employee of the pharmaceutical company that specifically deals with drug 
is pharmacist. Surely HC empowerment should also be made for company’s pharmacists. This 
is because the pharmacists who plays an important role in maintaining the quality of products 
made by the pharmaceutical companies. Indeed, this pharmacist once every five years must 
renew their competence to collect some credit points that must be met. Such statement was 
delivered by the informant M: 
 
"So usually like this. These pharmacists in every five years must renew their competence. 
Well they were first had to go through a competency test, later in the five years they had 
to collect 60 credits. If they can not collect it then they should follow the competency test 
again. So from that, the pharmacist should be actively attended seminars. So there is a 
two points, there is a four points so we should follow and we collect, within five years shall 
be collected at least 60 points "(excerpt of an interview with M) 
 
By constantly updating its competence, it is expected that knowledge, skills, and attitude owned 
by pharmacists can make pharmaceutical product quality maintained. 
Empowerment is not only done on the components of HC, but also about SC owned by 
pharmaceutical companies. Empowerment can be done by always improving technology, 
culture, and organizational structure in order to provide an opportunity to constantly innovate 
and develop ideas on reform. Innovation in the pharmaceutical company has always been at the 
different department that is research and development department. 
Technology has become an important part in the SC empowerment in the pharmaceutical 
company. This is certainly by the quality of medicines that will be generated. For the 
development of technological innovation, there are required as required in CPOB or innovation 
on the company's own desires. DS informant gives an example of rejuvenation machine to be 
done to meet CPOB standards. As DS informant following statement: 
 
"That's right sir, there must be rejuvenation. For example, the washer bottle pack. First, 
the wash bottle, the water can be circulated. If the bottle is already on the tube so, it is 
quite said to be washed like it has been circulated. Now, that the new rules prohibit it. 
Once used to wash the bottle then the water should be discarded. Well from there then 
we should replace the old machines we owned with a new ones according to the rules set 
by the government "(excerpt of an interview with DS) 
 
Innovation for the development of machinery, equipment, and technology can be caused 
by the presence of CPOB regulations and also from within the company itself. Innovation of the 
company can be done on the basis of a top down and bottom up. Top-down approach is usually 
associated with new machines from overseas suppliers, while that bottom-up usually at the level 
of production and also in the relationship or marketing. Source of marketing is usually because it 
is based on customer needs in the market. 
Empowerment can be done to the technology, machinery, and equipment is to accept 
product orders from other companies or by the product term "tolling". It can also be used to help 
improve the financial performance of the company. As M informant following statement: 
 
"Yes, it could be like that Sir. So if for the product itself has been completed, the machine 
still idling he should receive it "tolling" product. And it can indeed help improve the 
financial performance. So, to add income, so others should not have to buy the machine 
again "(excerpt of an interview with M) 
 
SC Empowerment including the aspects of organizational culture. That is, companies 
began entering or perform the steps in the innovation management has had to change the 
organizational culture into a culture that is able to absorb and empower creative ideas and 
innovative employees. To be able to build a culture of innovation, all employees must be able to 
exchange thoughts and ideas can come from employees.  
Empowerment is not only done for HC and SC only, but also to be done on the RC 
component on innovation management stage. At this stage the RC components are already 
grow even more than on the knowledge management stage. Empowerment to do at this stage is 
the use of media or marketing campaign that has begun to be developed by improving 
relationships with doctors, change the mindset of sales oriented to marketing oriented should 
have started on the long-term interests. Feedback from customers also have started to be 
considered and addressed to then performed on a product-related innovation. The use of IT 
should also have been started for mass marketing. Likewise, the CSR activities have started to 
do for the community. 
The use of appropriate media campaign has become one of the important parts in 
innovation management stage for OTC products. Similarly, that at this stage the company also 
has had to begin responds the market needs or complaints as well. For example, if there are 
complaints on product packaging, it should be quickly addressed by the company for then is 
performed an innovation on the product. Change of mindset or thinking of sales oriented 
towards marketing oriented should also be carried out by the company at this stage of 
innovation management. Company should have a long-term mindset that will have an impact on 
company performance. By doing marketing oriented so RC empowering will be easier to 
achieve because of the effort to do branding on the product has begun to appear on the 
innovation management stage. The use of IT as a medium for promotion and market mediation 
is also an important part at this stage, including the delivery of sustainable CSR also has to be 
considered for long-term interests. 
Based on the above results, the characteristics and the empowerment of the IC on the 
stage of innovation management are as follows: 
1. The outside company’s consultants have started to be used to obtain the innovation process. 
Source innovation from outside the company apart from the consultant also through 
marketing team. 
2. Innovation and creative ideas have started to grow from within the company, from the 
employees. That is, a culture of innovation and creative ideas has started to grow at this 
stage. 
3. Innovation of the new or reformulated products has been developed in the research and 
development department. That is, companies have started using the research and 
development department to innovate on pharmaceutical products 
4. HC Empowerment which can be done is training to grow and develop ideas, creativity, and 
innovation so it is rising to new ways, new more innovative work systems, and other creative 
aspects. To that end, the training should be focused on aspects of skill, attitude, and 
knowledge. Knowledge empowerment can be done with knowledge sharing between senior 
employees with juniors, and between experienced employees with new employees. 
Increasing the number and competence of pharmacists also become the part of the HC 
empowerment. 
5. SC Empowerment which can be done is to empower technology owned and optimize it. 
Technology or machinery may also be empowered to accept orders from other companies, 
known as “tolling” products. In addition, cultural empowerment organization towards 
innovative and creative culture, empowerment of research and development department is 
also important to do. 
6. RC Empowerment which can be done is to use the mass media for optimum imaging 
products and companies. Strengthening the marketing team to capture innovation in the 
market to be brought into the company. Empowerment of customer feedback for 
improvement or product innovation. Empowerment through CSR that is sustainable for the 
long term.  
 
Based on these characteristics, at this stage the HC empowerment which can be done is 
training to cultivate and develop ideas, creativity, and innovation giving rise to new ways, new 
more innovative work systems, and other creative aspects. To that end, the training should be 
focused on aspects of skill, attitude, and knowledge. Knowledge empowerment can be done 
with knowledge sharing between senior employees with juniors, and between experienced 
employees with new employees. Increasing the number and competence of pharmacists also 
become a part of the HC empowerment. Meanwhile, SC empowerment which can be done is to 
empower the technology and infrastructure owned by optimizing it. Technology or machinery 
may also be empowered to accept orders from other companies, known as “tolling” products. In 
addition, cultural organization empowerment towards innovative and creative culture, 
empowerment of research and development department is also important to do. RC 
empowerment which can be done is to use the mass media for optimum imaging products and 
companies. Strengthen the marketing team to capture innovation in the market to be brought 
into the company. There is customer feedback empowerment to get improvement or product 
innovation. RC empowerment at this stage is done through CSR that are still tentative.   
Based on the above, and also based on the text's meaning purposes of innovation 
management stages, the pharmaceutical companies in this stage has begun to find the 
resources so that innovation can begin to create new ways and new products faster. 
Pharmaceutical companies in this stage have started out from the internal management 
problems. That is, internal management is well defined so it can begin to move "out" and do 
new ways more innovative and creative. Source of pharmaceutical companies innovation is 
more from marketing team who saw the market and also of the employees. All component of IC 
namely HC, SC and RC supports the creation efforts for innovation and creativity. HC has 
begun to develop and empower all knowledge, experience, and skills they have to create new 
things and new creations. SC also support the creation of innovation to start the growth of a 
culture of innovation and provide ample opportunity to HC for innovation and creativity. Systems 
and procedures also provide an opportunity for employees to dare to try new things for the sake 
of being created new ways more innovative and faster. Likewise, the RC has begun to be able 
to capture the desires and changes in markets including consumer behavior so as to provide 
input to management innovation company. 
 
B.3. IC Empowerment in Intellectual Property Management Stage 
The purpose of the stages of intellectual property management is to be able to use the 
intellectual property to improve the competitive position of the organization and earn revenue. 
When described, there are some key words of the purpose of this stage that is using the 
intellectual property, improve the competitive position of the organization, and earn revenue. 
The meaning of "use intellectual property" is the company has to have intellectual property, for 
example the famous products (branded), images of good companies, have patents, trademarks, 
copyrights, and high competence and experienced employees. Meanwhile, the meaning of 
"improving the competitive position of the organization" means the company has a position and 
will strive to improve its position to the upper level and are also ready to compete with other 
companies in the same industry at the national level, regional asia, and also international. 
Accordingly, the meaning of "earn" is a result of the efforts of a sustained effort by the company 
to improve and leverage its intellectual property. 
At the time of the FGD, also discussed about the characteristics of the pharmaceutical 
companies in the stages of intellectual property management. By identifying these 
characteristics the it will facilitate the identification of empowerment that must be done in order 
to optimize the company's IC. Some of the opinion of  the FGD participants that the 
characteristic of the company in the intellectual property management stage is the process of 
selective recruitment of employees, their competency based human resource management, 
planning carrer system, efforts to continue to create brand company and brand product, a good 
relationship with doctors grade A, and the presence of a great marketing team. At this stage 
also that the company is able to work together with various parties, including the pharmaceutical 
companies overseas, human resources management has been doing competency-based 
human resource management, product innovation has led to the conglomeration in the health 
business from upstream to downstream, and no longer focus on drug-products. 
Based on these characteristics, the empowerment of the IC can be done by 
pharmaceutical companies in the stages of intellectual property management. HC 
empowerment at the beginning of the process is when the employee recruitment process as this 
will affect the next employee development process. If the input is good, it will be easier to 
develop employees in accordance with the wishes of the company. This is because at this 
stage, the role of HC should really required to create, develop, and use intellectual property 
owned to increase the competitiveness of companies. Accordingly, the HC standard on 
pharmaceutical companies above this level should be really experienced in his field and also 
has a very good competence. This is certainly in accordance with human resource management 
competency that has been applied to several major pharmaceutical companies. Similarly, the 
process of further development of human resources. In the process, it should have a healthy 
company should be able to plan in career planning system. That all was well planned over each 
position forward. In this regard, the KK informant give its opinion: 
 
"Ideally, the company is healthy if he never recruit certain positions from the outside. All 
has been planned through career planning. So that the HR director should know that this 
position will be retired and the level below will be ready to replace it. And need not be 
held rolling, the point that the employee knows that the work in this section is like this, if 
the QC section works like this. So he knows or has a lot of skill or multi-skill. Oh, it is turns 
out that the A is not suitable in this section but fit in the other sections and developing 
well. Then he will be forced there and plotted there. Until the highest in the section retired 
or resigned because there was an offer from another company, we are not confused. So 
it is that we prepare sir "(Opinion of KK when FGD) 
 
Although there should be a career planning system for HC owned by pharmaceutical 
companies, it is possible that the quality HC taken from other pharmaceutical companies. 
This was used to power marketing in the pharmaceutical company. That's what the company 
strategy in order to achieve intellectual property. 
HC Empowerment can also be done by empowering employees’ brainware. That is, 
the company should be able to develop the ability of the brain that is owned by the 
employees. The results of training, education, and knowledge sharing has been done by the 
company should be able to be synergy in producing works or new findings both for the 
system work better, new ways, or innovative products. Thus, an attempt to capture and 
utilize intellectual property company can be done more easily. 
Well, brainware empowerment becomes very important, not least with brain ware 
owned by marketing personnel. As a reference, the pharmaceutical company marketing 
personnel Foreign Investment Company (PMA) can be a very good example for HC in 
intellectual propertymanagement stage. This is due to product knowledge owned PMA 
pharmaceutical company med rep is very nice. They were able to explain much detail as 
possible, sometimes there is also a doctor who became MR in PMA pharmaceutical 
company. 
HC Empowerment component can also be performed on the pharmacist to maintain 
product quality. As statements of M informant, which is also a board of GP of Indonesia 
Pharmaceutical that pharmacists of large pharmaceutical companies can achieve a number 
of more than 100 people. With the increasing number of pharmacists in the pharmaceutical 
companies would be better ensure product quality. The following statement M informant: 
 
"So in the pharmaceutical industry, many pharmacists are absorbed. If it is for a large 
company it may be up to 100 pharmacists as Dexa Medica group with it may be 100 
pharmacists who are there "(quotation of an interview with M) 
 
Empowerment at the stage of intellectual property management is not just for the HC 
components, but applied also to the SC. In the SC component is related to the branded 
products, patent products, and also the products sold in the market or required by society. 
Empowerment should be done by pharmaceutical companies to all intellectual property 
owned through its products. For example, empowerment for ethical products off patent is to 
convince doctors that the product off this patent has the same benefits to the patent product. 
This is to be done by pharmaceutical companies if they have a product off patent of leader 
product. Empowerment on products that have branded this can be via an IP portfolio. For a 
pharmaceutical company that produces me too on the leader product, empowerment is to 
convince doctors that its product has the same benefits to the leader product for me too 
product. 
Another SC Empowerment component in the intellectual propertymanagement stage 
is to build and empower its data base system. The system's data base must complete all of 
the information related to the drug when it is produced and also when marketed and sold. 
Data base system is certainly very important as database support system that will be very 
useful for management decision making pharmaceutical companies. In so doing, 
pharmaceutical companies should be able to build a database system that can be used to 
manage intellectual property (intellectual property). 
Another SC Empowerment components are also corporate culture must change and 
empowerment at this intellectual property management stage. The corporate culture must 
change to the professional culture. Empowerment professional corporate culture should be 
performed on all aspects of each company's activities. The corporate culture that built and 
empowered to all employees will be the difference between a company that one with another 
company. This is particularly noticeable when in the "field" to a med rep between the 
domestic and foreign, including in terms of its facilities. 
Build and empower all matters related to the company's activities, such as building a 
data base system, maintain the quality of products, establishing a culture of professionalism 
is needed commitment and consistency of the vision and mission of the company which has 
been formulated previously. This is important because it is related to how the company and 
all its components can achieve the vision and mission. The steps that have been agreed 
from the beginning must be implemented in order to achieve the vision of the mission. 
Commitment and consistency of vision and mission is what should continue to be built and 
empowered in order to manage management. Several major pharmaceutical companies 
have implemented the balanced scorecard to map the company's strategy to do with the 
vision and mission of the target company. The result was remarkable, that there is a 
significant improvement in the performance of the company. 
Empowerment on RC components should also be made at intellectual property 
management stage. Companies that already at this stage must be able to build and 
empower the use of information technology (IT) to support all the activities of the company's 
operations, including in terms of marketing. Performance of pharmaceutical companies 
including the use of information technology will greatly affect trust the other party, such as a 
doctor. This relates to the company's brand associated with doctors for marketing ethical 
products. In the pharmaceutical industry in Indonesia is also a division of grade A, B, C, and 
D for each company. The company's reputation greatly affect the confidence of others, 
including foreign investment company that is definitely highly trusted by doctors. 
The company's reputation can also be built with different management strategies with 
other companies. One such strategy is the blue ocean strategy. The essence of the strategy 
is a strategy to conquer competitors by offering products or services that are not offered by 
other companies or also make a product or service that does not exist on the market. This is 
one way that should be built by pharmaceutical companies in the stages of intellectual 
property management. If pharmaceutical companies in developing and empowering this 
strategy, it will be easier to improve the competitive position of the company, and earn as 
goal of  intellectual property management stage. Some pharmaceutical companies are 
already applying the blue ocean strategy that increases performance. Another strategy is to 
be built and empowered the branding strategy and branding awareness. Although the 
strategy is very expensive, in the long run will be very useful and generating high revenues 
for the pharmaceutical companies. 
RC Empowerment for OTC products is to utilize promotional media either print or 
electronic media. Advertising expenditure reached a great value to be able to achieve the 
desired return. That is, that the selection of advertising media and also the brand 
ambassador should be able to lift the OTC product into a product that is easily remembered 
and appreciated by the public. Giving a drug name that is easy to remember is also 
important that the products sold in the community. 
RC empowerment can also be done in cooperation that has been done by 
pharmaceutical companies. Cooperation can be done by various parties, at home and 
abroad. Various interests can be achieved in a variety of such cooperation. For example, 
cooperation with foreign pharmaceutical companies have patented drug product. Indonesian 
pharmaceutical company can become a licensee or distributor to market the product patent. 
Other RC Empowerment is the aspect of CSR activities undertaken by pharmaceutical 
companies. CSR conducted by pharmaceutical companies consisting of two events, the 
event for the purpose of short-term and long-term. Short-term CSR Event for example is 
working with schools, neighborhood health center, health center for free drug delivery 
activities, and similar activities. long-term CSR events is more on the formation activities of 
pharmaceutical company's brand image in order to get the name of the public good, such as 
cooperation for the award on the best research in the field of pharmacy. CSR activities have 
to be empowered so as to improve the reputation of pharmaceutical companies for short-
term and long-term so that the sustainability the company is maintained. 
Based on the above results, the characteristics and the empowerment of the IC on the 
stages of intellectual property management are as follows: 
1. Several big pharmaceutical companies have implemented competency based human 
resource management and their career planning system. This means that HC 
management has done well. 
2. The company already has a good information technology for the production and 
marketing databases. 
3. good relationship with doctor grade A or doctor leader has been established. This is 
certainly very beneficial for ethical products of the company because it will be easier to 
market pharmaceutical products 
4. The company has a marketing team and a team of qualified sales force. This is related to 
how the marketing team was building a good relationship with doctors and KPDM in the 
hospital. 
5. The nominal amount of advertising spending is already very large, by making use of a 
wide variety of media. CSR activities has been carried out on an ongoing basis. Various 
forms of cooperation have been carried out by various parties, both inside and outside the 
country. 
6. Empowerment of HC to be done on competency-based human resource management 
and career planning system that HC can really deliver the best work for pharmaceutical 
companies. 
7. Empowerment of employee braindware, especially in the marketing needs to be done in 
order to spearhead the sales and marketing of pharmaceutical companies are marketing 
and also med rep. Likewise, the empowerment to pharmacist can be improved in terms of 
quantity and quality. 
8. SC Empowerment can be done by optimizing the role of branded products, product 
leader, the product off the famous patent owned by the company. Empowerment can be 
done with the IP portfolio. Another empowerment in the SC can be done on information 
technology, machinery, equipment, and also systems that are integrated data base or 
also electronic data processing (EDP) of the company. Empowerment also be done on 
corporate culture towards a professional culture. Likewise, the empowerment of vision, 
mission and strategy through various means of evaluation, for example with a balanced 
scorecard. 
9. RC Empowerment can be done to maximize the company's reputation to convince 
doctors to ethical products. Empowerment OTC products can be done by optimizing the 
role of the mass media, CSR activities. Various cooperation can be empowered to 
various corporate interests. 
 
Based on these characteristics, that at this stage, the empowerment of HC can be 
done by constantly developing career planning system that has been owned by the 
pharmaceutical company. If necessary employees (HC) from outside the company, of 
course, quality, competence, and experience were recruited to be really on top of the 
average employee in the company. In addition, pharmaceutical companies always improve 
and develop the knowledge, skills, and brain ware owned by each employee of the company. 
Meanwhile, the empowerment of the SC can be done by always strive to create a leader in 
product, brand product, and reputation of pharmaceutical companies. If the resulting product 
is a product leader but off patent, should try to convince the doctor that the off product is the 
same benefits of this patent with patent products. The use of information technology to 
support the operational activities of the company is also a part that should be empowered. 
Empowerment should also be made to the organizational culture towards a culture of 
professional organizations including the commitment and consistency to run the company's 
vision and mission that has been announced previously. RC empowerment can be done by 
continuing to strengthen the quality of the marketing team and sales force team, strengthen 
relationships with doctor leaders or the grade A, imaging through the mass media, and 
perform ongoing CSR. 
Based on the above, and also based on the text's meaning purposes of intellectual 
property management stages, that the pharmaceutical companies in this stage already have 
intellectual property, such as brand products have started to emerge, the brand image of the 
company is also well known, including the leader of the company's product. The existence of 
such a variety of intellectual property, pharmaceutical companies are able to obtain income 
(superior profit) and also capable of improving the competitive position of the company. At 
this stage, intellectual property owned by pharmaceutical company is not only associated 
with the drug alone, but already on other aspects. This means that pharmaceutical 
companies have a lot to diversify the product or also have a lot of business conglomerates. 
Diversification of medicinal products is to make the products immunity, dairy, food and 
beverage supplements, health drinks. The point is products that support health. Business 
conglomeratate of pharmaceutical companies with other businesses that still have relation 
with the pharmacy and medicine, for example, create a pharmacy, make health clinic. In fact, 
there are also efforts to conduct pharmaceutical business conglomerate from upstream to 
downstream, for example by building manufacturer or packer medicine bag, infusion tube, 
capsule bag, and other pharmaceutical preparations. Pharmaceutical companies already 
have the intellectual property will be easier to compete and earn revenue. Leader branded 
product or a product which is very beneficial for the pharmaceutical companies because the 
existing products more easily remembered by the people, for example when a headache, 
people will always remember Bodrex or Oskadon. Brand image of the company also greatly 
affects people's perceptions, such Kalbe Farma products must be good, pharmacies of Kimia 
Farma definitely complete. Things like this is called intellectual property or intellectual 
property. 
 
C. IC Research with Interpretive Accounting Research 
This IC research is designed with interpretive accounting research as been done by 
Hermawan (2013). This is done because the purpose of this research is to explore the IC 
empowerment through CICM. Thus the approach to research carried out in accordance with 
the purpose of the research is qualitative interpretive research. Indeed, as well as Hermawan 
(2013) stated that IC research can be classified into two major groups namely the IC 
research of financial and non-financial. Financial IC research more widely used to assess the 
financial performance of the company while non-financial IC research more widely used to 
build or explore the hidden assets for enhanced performance, competitiveness, and 
prosperity of the company (Hermawan, 2012, 2013, 2014). This division eventually also 
occur on the research method used. For financial IC research using quantitative research 
approaches while non financial IC research using qualitative research approaches including 
this IAR. 
IAR contribution of this research is to know the average position of the pharmaceutical 
companies in Indonesia in general when viewed from the CICM. The result is the average 
pharmaceutical company in Indonesia is still at the stage of knowledge management and 
innovation management. Only a few pharmaceutical companies only exist at the stage of 
intellectual property management. The results of the research is very likely to be obtained by 
IAR because researchers conducted in-depth interviews and focus group discussions. 
The next contribution of IAR in this research is by obtaining the characteristics of the 
pharmaceutical companies that are at every stage of the IC, which includes knowledge 
management, innovation management, and intellectual property management. These 
characteristics inherent in pharmaceutical companies in accordance with the concept of 
CICM (Al, Ali, 2003). For example, the characteristics of HC on stage pharmaceutical 
company in knowledge management is still limited funding and therefore contributes to the 
development of HC. Similarly, the example of the characteristics of pharmaceutical 
companies on stage innovation management in the empowerment SC, namely innovation 
and creative ideas have started to grow from within the company. Similarly, examples of the 
characteristics of the stages of empowerment RC intellectual property management that 
several major pharmaceutical companies are already implementing competency-based 
human resource management and their career planning system. Examples of this IC 
empowerment characteristics can only be done with IAR. Because according Kong and 
Ramia (2010), non-financial IC research like this that explores the hidden assets, tacit, non-
verbal dimension requires in-depth interviews and also the interpretation of the meaning of 
the key informant. 
IAR in more specific research on interpretive research (IR) in management accounting 
(Lukkaa and Modell, 2010). The relation of IR management accounting with this research is 
that this research successfully explores the non-financial activities in the form of the 
characteristics of companies in the empowerment of the IC at every stage of CICM that this 
research is able to produce solutions to improve business performance at every stage of 
knowledge management, innovation management, and intellectual property management. 
As Hermawan (2011b) noted that the correlation IC with management accounting practices 
lies in the non-financial activities and provide useful information for companies to identify 
hidden assets, measure, communicate the value trigger that is expected to benefit the 
development of information systems performance measurement and resource allocation in 
the company. 
 
5. Conclusion 
IC Empowerment can be done by CICM through three stages, namely knowledge 
management, innovation management, and intellectual property management. IC 
Empowerment through CICM perceived by informants is complete because it starts from the 
lowest stage to the top stage that is intellectual property management. IC research has 
produced findings that the average pharmaceutical company in Indonesia is still in the stage 
of knowledge management and innovation management. Only a few pharmaceutical 
companies are already at the stage of intellectual property management. When depicted as 
a triangle, it isdivided into three parts. The bottom, and most are pharmaceutical company on 
knowledge management stage. The middle section is a pharmaceutical company at the 
innovation management stage. The number of companies at this stage are not as many as 
the companies at the knowledge management stage. The top part of the triangle must be 
have little number than two parts below. This section is a pharmaceutical company that is at 
the intellectual property management stage. Another finding of this research is that 
empowerment can be performed on all components of the IC (human capital, structural 
capital and relational capital) and also at all levels CICM (knowledge management, 
innovation management, and intellectual property management). IC empowerment can be 
done at all stages of CICM and at all IC components by observing the characteristics of the 
pharmaceutical companies in each of these stages. Meanwhile, non-financial IC research 
like this is very possible to be implemented with IAR because they have to understand the 
meaning of the key informants. Moreover, this IC research should explore the hidden assets 
and non-financial activities that can be on the measurement of performance, company 
resource allocation, performance, and also competitiveness. 
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